Galera Therapeutics is focused on transforming radiotherapy for cancer patients by developing innovative therapies that aim to mitigate the toxicities associated with radiation treatment while enhancing its anti-cancer effectiveness. The company is pioneering the use of superoxide dismutase mimetics, which are designed to mimic the body’s natural enzymes that convert harmful superoxide molecules into less toxic hydrogen peroxide. This approach seeks to protect healthy tissues from the damaging effects of radiation-induced superoxides, which can lead to conditions such as severe oral mucositis (SOM) in patients undergoing treatment for head and neck cancer.

The company’s lead product, avasopasem manganese, is specifically developed to reduce the incidence of SOM and other radiotherapy-induced toxicities by rapidly converting toxic superoxides into hydrogen peroxide, thereby minimizing damage to healthy cells. Additionally, Galera is advancing rucosopasem manganese, a next-generation dismutase mimetic that acts as a radiosensitizer to enhance the efficacy of stereotactic body radiation therapy (SBRT) in treating lung and pancreatic cancers. Both compounds are currently in various stages of clinical development, with ongoing studies aimed at evaluating their effectiveness in improving patient outcomes during radiotherapy.

United States

Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.

Cancer

Digestive System Diseases

Infectious Diseases

Lung Diseases

Galera Therapeutics

Triple-negative breast cancer

<p class="font_7">Galera’s lead product candidate, avasopasem manganese (GC4419), is a highly selective small molecule superoxide dismutase (SOD) mimetic that is initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem manganese is designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen, protecting normal tissue from damage associated with radiation therapy. Left untreated, elevated superoxide can damage noncancerous tissues and lead to debilitating side effects, including oral mucositis (OM), which can limit the anti-tumor efficacy of radiation therapy.</p>

Tilarginine + paclitaxel

Metastatic breast cancer

Avasopasem + (fulvestrant +CDK4/6i)

Tilarginine + nab-paclitaxel + alpelisib 

COVID-19

Infectious disease

<p class="font_7">Galera’s lead product candidate, avasopasem manganese, is an investigational, highly selective small molecule superoxide dismutase (SOD) mimetic that is initially being developed for the reduction of radiation-induced severe oral mucositis (SOM), which is not yet approved. Avasopasem is designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen, protecting normal tissue from damage associated with radiation therapy. Left untreated, elevated superoxide can damage noncancerous tissues and lead to debilitating side effects, including oral mucositis (OM), which can limit the anti-tumor efficacy of radiation therapy.</p>

Galera Therapeutics

Company Details